168 related articles for article (PubMed ID: 15057574)
1. Therapeutic implications of antibacterial resistance in community-acquired respiratory tract infections in children.
Cunha BA
Infection; 2004 Apr; 32(2):98-108. PubMed ID: 15057574
[TBL] [Abstract][Full Text] [Related]
2. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.
Low DE; Pichichero ME; Schaad UB
Clin Pediatr (Phila); 2004 Mar; 43(2):135-51. PubMed ID: 15024437
[TBL] [Abstract][Full Text] [Related]
3. PROTEKT years 1-3 (1999-2002): study design and methodology.
Harding I; Felmingham D
J Chemother; 2004 Dec; 16 Suppl 6():9-18. PubMed ID: 15690682
[No Abstract] [Full Text] [Related]
4. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
5. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
[TBL] [Abstract][Full Text] [Related]
8. Microbial factors leading to recurrent upper respiratory tract infections.
Brook I
Pediatr Infect Dis J; 1998 Aug; 17(8 Suppl):S62-7. PubMed ID: 9727652
[TBL] [Abstract][Full Text] [Related]
9. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of upper respiratory tract infections (acute tonsillopharyngitis, acute rhinosinusitis, acute otitis media)].
Ludwig E
Orv Hetil; 2003 Sep; 144(38):1881-2. PubMed ID: 14596027
[No Abstract] [Full Text] [Related]
11. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
12. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
13. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections.
Ehrhardt AF; Russo R
Am J Med; 2001 Dec; 111 Suppl 9A():30S-35S discussion 36S-38S. PubMed ID: 11755441
[TBL] [Abstract][Full Text] [Related]
14. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
Clark JP; Langston E
Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
[TBL] [Abstract][Full Text] [Related]
15. Defining resistance: breakpoints and beyond implications for pediatric respiratory infection.
Pelton SI
Diagn Microbiol Infect Dis; 1996 Aug; 25(4):195-9. PubMed ID: 8937844
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance in bacterial pathogens among hospitalized children with community acquired lower respiratory tract infections in Dongguan, China (2011-2016).
He X; Xie M; Li S; Ye J; Peng Q; Ma Q; Lu X; Zhong B
BMC Infect Dis; 2017 Sep; 17(1):614. PubMed ID: 28893195
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
18. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotics in bacterial acute respiratory tract infection in children].
Tatochenko VK; Katosova LK
Antibiot Khimioter; 1999; 44(9):13-8. PubMed ID: 10511903
[TBL] [Abstract][Full Text] [Related]
20. CIPROFLOXACIN RESISTANCE PATTERN AMONG BACTERIA ISOLATED FROM PATIENTS WITH COMMUNITY-ACQUIRED URINARY TRACT INFECTION.
Reis AC; Santos SR; Souza SC; Saldanha MG; Pitanga TN; Oliveira RR
Rev Inst Med Trop Sao Paulo; 2016 Jul; 58():53. PubMed ID: 27410913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
